Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Sun Pharma Explores Funding Mix for $12 Billion Organon Deal
Global lenders to Sun Pharmaceutical Industries Ltd. are weighing multiple financing options for its proposed $12 billion acquisition of New York-listed healthcare company Organon & Co., according to people familiar with the matter. The Indian…
Sun Pharma Organon Acquisition: Strategic Expansion, Financial Impact, and Future Outlook
Sun Pharmaceutical Industries' landmark $11.75 billion acquisition of US-based Organon & Co is set to strategically expand its portfolio into high-growth women's health and biosimilars segments, despite potential integration complexities and debt…
White House estimates Trump's Big Pharma dealmaking will save Americans $529 billion over the next 10 years
White House economists estimate that President Donald Trump's deals with pharmaceutical companies to drop some of their U.S. prescription drug prices to what they charge in other countries could save $529 billion over the next 10 years. The…
AI is saving pharma billions in manufacturing and back-office work, just not in the lab
According to Eli Lilly's digital chief, AI in pharma has barely moved the needle on actual drug discovery, and is instead paying off in the rest of the process. Despite billions in investment, there's no proof AI is making clinical trials more…
Purdue Pharma's opioid prosecution enables bankruptcy settlement
On 28 April, a US federal court sentenced Purdue Pharma to pay over $5 billion (£3.7 billion) in criminal penalties for its aggressive and misleading marketing of opioid drugs including OxyContin (oxycodone), which contributed to the US…
Purdue Pharma reaches $7.4 billion settlement over opioid crisis
Purdue Pharma reaches $7.4 billion settlement over opioid crisis LIVE IN THE NEWSROOM TODAY. I'M MARTINEZ, NBC FIVE NEWS. THANKS. $7.4 BILLION SETTLEMENT WITH PURDUE PHARMA OVER THE OPIOID CRISIS IS NOW LEGALLY IN EFFECT. IT WAS BACK IN 2016 WHEN…
Pharma's reputation among patient groups rose last year, but concerns remain over access and pricing
The pharmaceutical industry saw its reputation among patient groups inch up last year, but the rise masks fresh concerns about the extent to which some companies are sufficiently focusing on patient needs, according to a new survey. Of more than…
Royalty Pharma (NASDAQ:RPRX) Hits New 52-Week High - Still a Buy?
Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) shares reached a new 52-week high during trading on Tuesday. The company traded as high as $50.50 and last traded at $50.3080, with a volume of 595 shares trading hands. The stock had previously…
Waters CEO highlights China as key innovation source in the biopharma market
Waters CEO Udit Batra highlighted China as a global biopharmaceutical powerhouse. He said that innovation has fueled a rapid expansion of contract manufacturers moving into full drug development. Waters CEO Udit Batra said China is emerging as a…
Nuvectis Pharma (NASDAQ:NVCT) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS
Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.04, FiscalAI reports. Shares of…
Innate Pharma (NASDAQ:IPHA) Shares Down 0.7% - Here's What Happened
Shares of Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA - Get Free Report) were down 0.7% on Monday. The company traded as low as $1.43 and last traded at $1.43. Approximately 36,983 shares traded hands during mid-day trading, an increase of 21%…
Indian Stock Markets Decline Amid Geopolitical Concerns, Rupee Weakness
Indian stock markets, including the Sensex and Nifty, saw declines in early trade, primarily driven by escalating geopolitical tensions in the Strait of Hormuz and the rupee's depreciation to a record low against the US dollar. Indian equity…
Dorian LPG: Rates Are Already Above My Bull Case -- Market Still Hasn't Caught Up (NYSE:LPG)
Dorian LPG (LPG) is rated Strong Buy as realized TCE rates now exceed prior bull-case assumptions, driving significant upside potential. LPG's current quarter is largely de-risked, with 99% of days fixed above $58k/day, implying robust earnings…
Jim Cramer's top 10 things to watch in the stock market Tuesday
My top 10 things to watch Tuesday, May 5 1. Stocks are headed for a higher open, supported by falling oil prices. Strong corporate earnings and a fragile ceasefire agreement between the U.S. and Iran are in focus. Yesterday was a down day for the S…
The Trust Equation Health Marketers Must Solve
The future of brands gets decided here. Join the industry's top marketers at Brandweek for the ideas, insights, and connections shaping what's next. Get your ticket. This post was created in partnership with Doceree Unlike in other industries…
Receive a Daily briefing on Pharma Industry News
Get Started